Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 5:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 87 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: carbamazepine Clear all
Completed Phase 2 Interventional

Carbamazepine Treatment of Cocaine Dependence - 1

NCT00000242
View directory record Official record
Conditions
Cocaine-Related Disorders, Substance-Related Disorders
Interventions
Carbamazepine
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 1997
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 7, 2017 · Synced Sep 30, 2026, 5:10 PM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Potential Drug-Drug Interactions of E2086 in Healthy Participants

NCT07766369
View directory record Official record
Conditions
Healthy Volunteers
Interventions
E2086
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
93 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Sep 30, 2026, 5:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Effects of Itraconazole or Carbamazepine on LY3537982 in Healthy Participants

NCT05860933
View directory record Official record
Conditions
Healthy
Interventions
LY3537982, Itraconazole, Carbamazepine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
2
States / cities
San Antonio, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 8, 2024 · Synced Sep 30, 2026, 5:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole, Carbamazepine, Quinidine and Fluconazole on the Pharmacokinetics and Safety of EDP-323.

NCT06847464
View directory record Official record
Conditions
RSV Infection, Drug Drug Interaction (DDI)
Interventions
EDP-323, Itraconazole, carbamazepine, Quinidine, fluconazole
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Sep 30, 2026, 5:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug-drug Interaction Study of S-892216 Coadministered With Carbamazepime to Healthy Adult Participants

NCT06751017
View directory record Official record
Conditions
COVID-19
Interventions
S-892216, Carbamazepine
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced Sep 30, 2026, 5:10 PM EDT
Completed Phase 3 Interventional Results available

Evaluating Long Term Safety of Lacosamide (LCM) to Carbamazepine Controlled-release (CBZ-CR); Initial Monotherapy in Epilepsy Subjects 16 Years and Older

NCT01465997
View directory record Official record
Conditions
Epilepsy, Monotherapy
Interventions
Lacosamide, Carbamazepine-Controlled Release (CBZ-CR)
Drug
Lead sponsor
UCB BIOSCIENCES GmbH
Industry
Eligibility
Not listed
Enrollment
551 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
9
States / cities
Alabaster, Alabama • Huntsville, Alabama • Little Rock, Arkansas + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2018 · Synced Sep 30, 2026, 5:10 PM EDT
Completed Phase 4 Interventional

Equetro for the Treatment of Mania in Children Ages 6-12 With Bipolar Disorder

NCT00181870
View directory record Official record
Conditions
Bipolar Disorder, Mania
Interventions
carbamazepine ER (Equetro)
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
6 Years to 12 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 22, 2010 · Synced Sep 30, 2026, 5:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-Drug Interaction Study Between EDP-235, Itraconazole, Carbamazepine and Quinidine in Healthy Subjects.

NCT05594602
View directory record Official record
Conditions
COVID-19
Interventions
EDP-235, Itraconazole, Carbamazepine, Quinidine
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 27, 2023 · Synced Sep 30, 2026, 5:10 PM EDT
Completed Phase 3 Interventional Results available

Safety and Tolerability of OXC XR as Adjunctive Therapy in Subjects With Refractory Partial Epilepsy

NCT00908349
View directory record Official record
Conditions
Partial Epilepsy
Interventions
Oxcarbazepine XR
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 66 Years
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
20
States / cities
Huntsville, Alabama • Northport, Alabama • Phoenix, Arizona + 17 more
Source: ClinicalTrials.gov public record
Updated May 31, 2017 · Synced Sep 30, 2026, 5:10 PM EDT
Completed Phase 2 Interventional

Carbamazepine Treatment for Cocaine Dependence - 5

NCT00000191
View directory record Official record
Conditions
Cocaine-Related Disorders
Interventions
Carbamazepine
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
21 Years to 51 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1991 – 1994
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 28, 2015 · Synced Sep 30, 2026, 5:10 PM EDT
Recruiting No phase listed Observational

Physiological-based Pharmacokinetics Approach to Medication Exposure During Pregnancy and Breastfeeding

NCT05450978
View directory record Official record
Conditions
Epilepsy, Pregnancy Related
Interventions
Lamotrigine, Levetiracetam, Oxcarbazepine
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Sep 30, 2026, 5:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Drug-Drug Interaction (DDI) Study of Orforglipron With Carbamazepine in Healthy Participants

NCT06370728
View directory record Official record
Conditions
Healthy
Interventions
Orforglipron, Carbamazepine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
21 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Sep 30, 2026, 5:10 PM EDT
Terminated Phase 3 Interventional Results available

Cognitive AED Outcomes in Pediatric Localization Related Epilepsy (COPE)

NCT01891890
View directory record Official record
Conditions
Epilepsy, Partial, Epilepsy, Localization Related
Interventions
Oxcarbazepine, Levetiracetam, Lamotrigine
Drug
Lead sponsor
Emory University
Other
Eligibility
5 Years to 16 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
14
States / cities
Little Rock, Arkansas • San Diego, California • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2017 · Synced Sep 30, 2026, 5:10 PM EDT
Completed Phase 1 Interventional

Ph I Oral Topotecan and Temozolomide for Patients With Malignant Gliomas

NCT00610571
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma, Anaplastic Astrocytoma
Interventions
Oral Topotecan and Temodar
Drug
Lead sponsor
Katy Peters
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 25, 2013 · Synced Sep 30, 2026, 5:10 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Study of the Effects of Itraconazole and Carbamazepine on LY3410738 in Healthy Participants

NCT05205447
View directory record Official record
Conditions
Healthy
Interventions
LY3410738, Itraconazole, Carbamazepine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Dec 28, 2022 · Synced Sep 30, 2026, 5:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-Drug Interaction Potential of Mavorixafor

NCT06914869
View directory record Official record
Conditions
Healthy Participants
Interventions
Mavorixafor, Carbamazepine, Efavirenz
Drug
Lead sponsor
X4 Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Sep 30, 2026, 5:10 PM EDT
Completed Not applicable Interventional Results available

Carbamazepine for the Treatment of Chronic Post-Traumatic Brain Injury Irritability and Aggression

NCT00621751
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Carbamazepine, Placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
16 Years to 75 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 22, 2022 · Synced Sep 30, 2026, 5:10 PM EDT
Completed Phase 3 Interventional Results available

Trial Comparing the Efficacy and Safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR); Initial Monotherapy in Epilepsy; Subjects Aged 16 and Older

NCT01243177
View directory record Official record
Conditions
Epilepsy, Monotherapy
Interventions
Lacosamide, Carbamazepine-Controlled Release
Drug
Lead sponsor
UCB BIOSCIENCES GmbH
Industry
Eligibility
16 Years and older
Enrollment
888 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
15
States / cities
Alabaster, Alabama • Huntsville, Alabama • Phoenix, Arizona + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Sep 30, 2026, 5:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Carbamazepine on Dolutegravir Pharmacokinetics in Healthy Adult Subjects

NCT01967771
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
DTG, CBZ
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 27, 2014 · Synced Sep 30, 2026, 5:10 PM EDT
Completed Phase 2 Interventional

Pharmacotherapy and Intensive Treatment of Drug Abuse - 1

NCT00000217
View directory record Official record
Conditions
Cocaine-Related Disorders, Substance-Related Disorders
Interventions
Carbamazepine
Drug
Lead sponsor
University of Kansas
Other
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1990
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 16, 2015 · Synced Sep 30, 2026, 5:10 PM EDT
Terminated Phase 1 Interventional

Oxcarbazepine Plus Morphine in Patients With Refractory Cancer Pain

NCT02078089
View directory record Official record
Conditions
Cancer
Interventions
Morphine, Oxcarbazepine
Drug
Lead sponsor
Costantine Albany
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
2
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 31, 2017 · Synced Sep 30, 2026, 5:10 PM EDT
Terminated Phase 2 Interventional Results available

Carbamazepine in Severe Liver Disease Due to Alpha-1 Antitrypsin Deficiency

NCT01379469
View directory record Official record
Conditions
Alpha-1-antitrypsin Deficiency, Liver Cirrhosis
Interventions
Drug-Carbamazepine (Tegretol XR), Carbamazepine (Tegretol XR) Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
14 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
3
States / cities
St Louis, Missouri • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 12, 2021 · Synced Sep 30, 2026, 5:10 PM EDT
Not listed Phase 4 Interventional

Open Label Study of Lithium Plus Extended-Release Carbamazepine (ERC-CBZ) for Rapid Cycling Bipolar Disorder

NCT00325286
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Lithium Plus Extended- Release Carbamazepine
Drug
Lead sponsor
Creighton University
Other
Eligibility
19 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 14, 2007 · Synced Sep 30, 2026, 5:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Open-label Trial to Evaluate the Effect Carbamazepine on Darigabat Pharmacokinetics in Healthy Adult Participants

NCT05824143
View directory record Official record
Conditions
Healthy Participants
Interventions
Darigabat, Carbamazepine
Drug
Lead sponsor
Cerevel Therapeutics, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Aug 3, 2023 · Synced Sep 30, 2026, 5:10 PM EDT